1 © 2025 Artivion, Inc. Corporate Overview May 2025 FORWARD-LOOKING STATEMENT These statements include our belief that we have driven and can continue to drive sustained double digit revenue growth and 2x+ EBIDTA Growth as a result of our highly differentiated highly defendable base business, our high growth stent graft business and our leverageable global infrastructure; our estimated total addressable markets for preservation services (human tissue), mechanical heart valves, and surgical sealants are $150 ...

Summary of Artivion (AORT) Conference Call Company Overview - **Company**: Artivion (AORT) - **Industry**: Medical Devices, specifically focused on aortic treatments Key Points and Arguments Market Potential and Growth Strategy - Artivion operates in multiple Total Addressable Markets (TAMs) that, while individually smaller, collectively provide a durable growth runway [2][4] - The company is focused on the aortic segment, particularly advanced stent grafts, with a global market for stents and stent grafts estimated at $4 billion, of which $2 billion is in advanced stent grafts [5][6] - Artivion's pipeline includes several products with upcoming PMA submissions, including AMDS, NexSys, and Arecibo, which are expected to contribute to growth every 18 months [9][10] Product Pipeline and Innovations - **AMDS**: Expected PMA approval by mid-2026, with a TAM of over $500 million [12][13] - **NexSys**: A pivotal trial with 60 patients showed promising results, with a focus on chronic dissections [32][33] - **Arecibo**: A product for total replacement of the aortic arch, with trials expected to start later this year [8] - The company has a unique patented technology for aortic dissection that significantly reduces mortality rates [15][16] Financial Performance and Projections - Artivion aims for EBITDA growth at twice the rate of top-line growth, driven by margin expansion and operational efficiencies [69][71] - The company has successfully reduced leverage and improved cash flow, with a focus on maintaining reasonable debt levels while funding growth initiatives [45][46] Sales and Market Penetration - The existing sales force is deemed adequate for launching new products, with no immediate plans for expansion [21][22] - The company is actively working with over 150 accounts to navigate hospital bureaucracy for product adoption [23][24] Risks and Challenges - The primary risk to growth acceleration is the timing of hospital bureaucracy related to product adoption [68] - The company experienced a cyber attack that impacted supply chains, but recovery is expected by the end of Q3 [63][66] Competitive Landscape - Artivion's On X mechanical valve has shown a 14% CAGR over the past eight years, with a TAM of $250 million [54] - Recent studies indicate a mortality benefit for mechanical valves, opening up additional market opportunities [58][61] Conclusion - Artivion is positioned for significant growth in the aortic medical device market, with a strong pipeline of innovative products and a focus on operational efficiency and margin expansion. The company is navigating challenges related to market entry and hospital adoption but remains optimistic about future performance.

Core Viewpoint - Artivion, Inc. has successfully closed transactions related to privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due 2025, significantly reducing its outstanding debt and enhancing its financial position [1][3]. Financial Transactions - The exchange agreements involved the conversion of approximately $99.54 million of Notes into 4,334,347 shares of common stock, along with a cash payment of approximately $1.7 million for accrued and unpaid interest [2]. - Following the transactions, only about $0.46 million in principal amount of the Notes remains outstanding [2]. Management Commentary - The CEO of Artivion highlighted that the retirement of the convertible notes is a significant milestone that reduces leverage ratios and enhances balance sheet flexibility [3]. Advisory Role - J. Wood Capital Advisors LLC served as the financial advisor to Artivion during these exchange transactions [4]. Company Overview - Artivion, Inc. is a medical device company focused on solutions for cardiac and vascular surgery, particularly in treating aortic diseases, with a product range that includes aortic stent grafts, surgical sealants, mechanical heart valves, and implantable tissues [7].

ATLANTA, May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in e ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission file number: 1-13165 ARTIVION, INC. (State or other jurisdiction of incorporation or organization) 1655 ...

Core Viewpoint - Artivion (AORT) reported quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share, representing a 50% earnings surprise [1] - The company posted revenues of $98.98 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.19% [2] Financial Performance - Artivion's earnings of $0.06 per share are unchanged from the same quarter last year, and the company has surpassed consensus EPS estimates two times over the last four quarters [1][2] - The company has topped consensus revenue estimates three times in the last four quarters, with year-ago revenues of $97.43 million [2] Stock Performance - Artivion shares have declined approximately 18.4% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The current Zacks Rank for Artivion is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $108.7 million, and for the current fiscal year, it is $0.68 on revenues of $426.65 million [7] - The outlook for the Medical - Instruments industry is positive, ranking in the top 28% of over 250 Zacks industries, suggesting potential for outperformance [8]

Artivion (AORT) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Laine Morgan - Associate Vice PresidentPatrick Mackin - Chairman , President & CEOLance Berry - Executive VP & CFOJohn McAulay - AVPSuraj Kalia - Managing DirectorDaniel Stauder - Director - Equity ResearchJeffrey Cohen - MD - Equity Research Conference Call Participants Frank Takkinen - Senior Research AnalystMichael Matson - Senior Analyst Operator Greetings. Welcome to our Ativian's First Quarter twenty twenty five Financ ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $99 million, reflecting a 4% increase compared to Q1 2024 [20] - Adjusted EBITDA increased approximately 1% from $17.3 million to $17.5 million in Q1 2025 [20] - Adjusted EBITDA margin was 17.7%, relatively flat compared to the previous year [21] - Gross margins decreased to 64.2% from 64.6% year over year due to lower revenue from higher margin products [22] Business Line Data and Key Metrics Changes - Strength graft revenues grew 19% on a constant currency basis in Q1 2025 [8] - On X revenue increased by 11% year over year on a constant currency basis [11] - BioGlue revenues grew 9% on a constant currency basis [12] - Tissue processing revenues declined 23% year over year due to the backlog caused by a cybersecurity incident [12] Market Data and Key Metrics Changes - Latin America and Asia Pacific saw constant currency revenue growth of 268% and 14% respectively in Q1 2025 [13] - North America revenues declined by 6% compared to Q1 2024 [21] - EMEA revenues increased by 14% year over year [21] Company Strategy and Development Direction - The company is focused on ramping up On X supply and clearing the tissue processing backlog, with expectations to be fully caught up by the end of Q3 2025 [7][13] - The ongoing launch of AMDS in the U.S. is a key growth driver, with approximately 150 facilities actively seeking approvals [10][11] - The company aims to leverage positive clinical data to expand market share for On X valves, particularly among younger patients [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth and twice that rate for EBITDA in the future [19][29] - The company raised its full-year 2025 revenue guidance to a constant currency growth range of 11% to 14% [24] - Management noted that the impact of the cybersecurity incident is being resolved, with expectations for a return to normalcy in operations [6][29] Other Important Information - The company incurred approximately $4.7 million in Q1 related to the cybersecurity incident, which is excluded from adjusted EBITDA [22] - The net leverage ratio improved to 4.0 from 4.5 year over year [24] - The company does not anticipate the need to raise additional capital to fund its operations in the foreseeable future [22] Q&A Session Summary Question: Contribution of AMDS to growth and onboarding of facilities - Management indicated that AMDS contributed to the strong growth but did not break out specific numbers. They are encouraged by the reception from the clinical community and the onboarding process is progressing well [36][38] Question: Expectations for tissue growth recovery - Management expects to return to mid-single-digit growth for tissue processing by the end of the year, with the backlog being cleared in Q2 and Q3 [40][42] Question: Cash flow expectations for the year - Management expects to be free cash flow positive for the year, despite Q1 being seasonally high in expenses [54][56] Question: Growth rates for On X and stent grafts - Management expects On X to continue double-digit growth and stent grafts to grow at a mid-teens rate, with AMDS expected to improve overall growth rates [64][66] Question: Timing for acquiring Endospan - The option to acquire Endospan will trigger upon FDA approval, expected in the second half of 2026, with a decision required within 90 days of approval [72][74] Question: Feedback on Nexus data and market opportunity - Management expressed optimism about the Nexus data and its potential market impact, noting that the mortality benefits could lead to increased adoption [80][82]

Artivion (AORT) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Laine Morgan - Associate Vice PresidentPatrick Mackin - Chairman , President & CEOLance Berry - Executive VP & CFOJohn McAulay - AVPSuraj Kalia - Managing DirectorDaniel Stauder - Director - Equity ResearchJeffrey Cohen - MD - Equity Research Conference Call Participants Frank Takkinen - Senior Research AnalystMichael Matson - Senior Analyst Operator Greetings. Welcome to our Ativian's First Quarter twenty twenty five Financ ...

1Q 2025 Earnings Presentation May 5, 2025 1 © 2025 Artivion, Inc. FORWARD-LOOKING STATEMENTS Statements made in this presentation that look forward in time or that express management's beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs and expectations about our future revenue, ye ...